Studies on ritipenem acoxil in the treatment of surgical infections
スポンサーリンク
概要
- 論文の詳細を見る
The antibacterial activity, clinical efficacy and safety of ritipenem acoxil (RIPM-AC), a new oral penem, were evaluated in the treatment of surgical infections.<BR>1) Antibacterial activity<BR>Ritipenem (RIPM), the active form of RIPM-AC, showed potent activity against gram-positive cocci, with an MIC<SUB>90</SUB> of 0.10μg/ml for methicillin-sensitive <I>Staphylococcus aureus</I>, but the activity of RIPM against methicillin-resistant <I>Staphylococcus aureus</I> was inferior. The MIC<SUB>50</SUB> and MIC<I>90</I> of RIPM against coagulase-negative Staphylococci were 0.20μ/ml and 50μ/ml, respectively. Against <I>Enterococcus</I> spp., the MIC<I>50</I> and MIC<I>90</I> were both 6.25μ/ml.<BR>Against gram-negative rods, the MIC<SUB>90</SUB> of RIPM was 0.78μg/ml for <I>Escherichia coli</I> and<I>Klebsiella pneumoniae</I>. Against <I>Klebsiella oxytoca, Enterobacter cloacae, Serratia marcescens</I>and<I>Pseudomonas cepacia</I>, the MIC<SUB>50</SUB> were 0.78, 3.13, 3.13 and 0.39μ/ml, respectively. The respective MIC<SUB>90</SUB> of RIPM were 6.25, 25, 100 and 25μg/ml. Against <I>Enterobacter aerogenes, Citrobacter freundii</I>and<I>Proteus mirabilis</I>, the MIC<SUB>50</SUB> were 6.25, 3.13 and 6.25μg/ml. The MIC<SUB>90</SUB> were all 6.25μg/ml. The MIC<SUB>50</SUB> of RIPM was 100 or > 100μg/ml for <I>Pseudomonas aeruginosa, Acinetobacter calcoaceticus and Xanthomonas maltophilia</I>.<BR>2) Clinical study<BR>RIPM-AC was orally dosed to 20 patients: 5 with subcutaneous abscess, 4 with phlegmon, 3 with infected atheroma, 2 with felon, 1 with carbuncle, 1 with folliculitis, 2 with wound infection and 2 with mastitis.<BR>The clinical efficacy of RIPM-AC was excellent in 7, good in 11 and fair in 2, the efficacy rate being 90.0%. No side effects or abnormal laboratory test findngs were observed in any of the cases.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.